Compounds and methods for blocking apoptosis and inducing autophagy
AssigneePresident and Fellows of Harvard College
InventorsJunying Yuan, Heng Zhao, Daichao Xu, Mingzhi Jin, Hong Zhu, Gregory D. Cuny
Life of this patent
Estimating the term…
Abstract
Disclosed herein are small molecules that inhibit apoptosis and promote autophagy through the TRADD pathway, and their use for treatment of neurodegenerative diseases. Methods of preparing these small molecules and medicinal efficacy are described.
Claims35
i) A method of treating a neurodegenerative disease, ischemic brain injury, amyloidosis, inflammatory bowel diseases, liver diseases or a metabolic disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, or a compound selected from
- or a pharmaceutically acceptable salt thereof;
- or
- ii) a method of blocking apoptosis and/or inducing autophagy in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, or a compound selected from
- or a pharmaceutically acceptable salt thereof;
- or
- iii) an in vitro method of blocking apoptosis and/or inducing autophagy in a cell, comprising contacting the cell with a compound of Formula I, or a compound selected from
- or a pharmaceutically acceptable salt thereof;
- or
- iv) a method of promoting cellular recruitment of TRADD to complex I in a cell, comprising contacting the cell with a compound of Formula I, or a compound selected from
- or a pharmaceutically acceptable salt thereof:
- wherein the compound of Formula I has the following structure:
- wherein
- L is CH2, NR1a, heteroaryl or S(O)n, where n is 0, 1, or 2;
- R1a is independently selected from H, CN, alkyl, and aryl;
- R3 is selected from H, alkyl, and aryl;
- R4 is selected from H, alkyl, and aryl;
- R4′ is selected from H, alkyl, and aryl;
- R5 is selected from H, alkyl, aryl, heteroaryl, —(CH2)pCONR6R7 where p is 0, 1, or 2,
- —CH2NR6R7, —CH(OH)NR6R7, —CH(OH)CH2-cycloalkyl, —CH(OH)CH2-NHcycloalkyl, and —CR10═CHR11;
- R6 is selected from H, alkyl, C3-8cycloalkyl, aryl, and -NHcycloalkyl;
- R7 is selected from H and alkyl;
- or R6 and R7, taken together with the nitrogen atom to which they are attached, form a heterocyclyl;
- R10 is selected from H and halo;
- R11 is cycloalkyl;
- R13 is absent or alkyl, where the alkyl forms an iminium group;
- and
- (a) R1 and R2 are each independently selected from H, CN, alkyl, and aryl;
- or
- (b) R1 and R2, taken together with the atoms to which they are attached, form a heterocyclyl of Formula IA:
- R8 and R8′ are each independently selected from H, alkyl, and aryl;
- or
- (c) R1 and R2, taken together with the atoms to which they are attached, and R3 and R4, taken together with the atoms to which they are attached, form a bicycle of Formula IB:
- R8 and R8′ are each independently selected from H, alkyl, and aryl;
- further wherein when R5 is —(CH2)0CONR6R7, then R7 and R4, taken together with the atoms to which they are attached, may form a heterocyclyl of Formula IC:
3-4. (canceled)
(canceled)
11-12. (canceled)
(canceled)
A compound of Formula II:
- wherein
- L is NR1a or S;
- R1a is independently selected from CN, alkyl, and aryl;
- (a) R1 and R2 are each independently selected from CN, alkyl, and aryl, or
- (b) R1 and R2, taken together with the atoms to which they are attached, form a heterocyclyl of
- Formula IIA:
- wherein R8 and R8′ are each H or alkyl;
- R3 is selected from H, alkyl, and aryl;
- R4 is selected from H, alkyl, and aryl;
- R4, is selected from H, alkyl, and aryl;
- R5 is selected from aryl, —(CH2)pCONR6R7 where p is 0 or 2, —CH2NR6R7, —CH(OH)NR6R7, and —CR10═CHR11;
- R6 is selected from alkyl, aryl, and C3-8cycloalkyl, such as C7-8cycloalkyl or C3-4cycloalkyl;
- R7 is selected from H and alkyl,
- or R6 and R7, taken together with the nitrogen atom to which they are attached, form a heterocyclyl;
- R10 is H;
- R11 is cycloalkyl;
- R13 is absent or alkyl, where the alkyl forms an iminium group,
- or a pharmaceutically acceptable salt thereof,
- provided the compound of Formula II is not:
(canceled)
(canceled)
(canceled)
(canceled)
A compound selected from
Dependencies are inferred from the claim text.